ForPatients
by Roche

Fallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal NeoplasmsOvarian Cancer

An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Country	NCT01932125 ML28446

The clinical trial information herein is sourced from public registries such as ClinicalTrials.gov, EuClinicalTrials.eu, and ISRCTN.com. Additional patient-friendly (lay) content has been prepared by Roche to support understanding.

Official Title:

An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice

Trial Summary:

This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data will be collected from eligible patients until death, withdrawal of consent, loss to follow-up, or study closure.

Hoffmann-La Roche
Sponsor

Phase

NCT01932125 ML28446
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
Female	# 18 Years	No

Inclusion Criteria:

© 2022 F. Hoffmann-La Roche Ltd

- Prescribed to receive bevacizumab or already ongoing on treatment with bevacizumab for advanced/ metastatic ovarian cancer, fallopian tube cancer or primary peritoneal cancer (FIGO Stage IIIb, IIIc and IV) according to routine clinical practice

Exclusion Criteria:

- Not eligible for treatment with bevacizumab according to the local prescribing information

© 2022 F. Hoffmann-La Roche Ltd